COVID-19 in MS

202036 citationsJournal Articlegold Open Access

Authors

James D. Bowen · Multiple Sclerosis Center of Atlanta

Justine Brink · Multiple Sclerosis Center of Atlanta

Ted R. Brown · Multiple Sclerosis Center of Atlanta

Elisabeth B. Lucassen · Multiple Sclerosis Center of Atlanta

Kyle Smoot · Multiple Sclerosis Center of Atlanta

Annette Wundes · Multiple Sclerosis Center of Atlanta

Pavle Repovic

Abstract

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalization. Mortality is higher with cardiovascular disorders, diabetes, and older age.1

Topics & Keywords

COVID-19 Clinical Research Studies Long-Term Effects of COVID-19 SARS-CoV-2 and COVID-19 Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology Neuroimmunology & Neuroinflammation

Volume 7, Issue 5

DOI: 10.1212/nxi.0000000000000783

Field-Weighted Citation Impact: 0.87